Tribbles pseudokinase 2 (TRIB2)

Tribbles pseudokinase 2 (TRIB2) is a member of the tribbles family of pseudokinases, classified within the CAMK (Ca^2+/calmodulin-dependent protein kinase)-related subfamily but distinct in lacking canonical kinase activity due to divergence in key catalytic motifs[1][2][3]. TRIB2 functions primarily as a molecular adaptor and scaffold, influencing diverse signaling networks including those involving AKT kinase, MAPK proteins, C/EBP transcription factors, and cell cycle phosphatases such as CDC25[2][3][5]. It regulates protein stability by recruiting E3 ubiquitin ligases, which leads to degradation of targeted signaling molecules[2][3]. TRIB2 has been implicated in cell proliferation, survival, differentiation, and apoptosis, with overexpression or mutation linked to malignancies such as leukemia, melanoma, hepatocellular carcinoma, lung cancer, and osteosarcoma, as well as to certain metabolic diseases[2][3][5][6]. Structurally, TRIB2 is defined by a pseudokinase domain with unique sequence and conformational properties, including atypical ATP-binding, and is subject to highly regulated protein-protein interactions[1][3][4]. Although not an active kinase, its ATP-binding site can be weakly targeted by small molecules in engineered mutants, making it a potential drug target and a subject of ongoing pharmacological research[1][3]. No selective drugs are approved for TRIB2 as of 2025, but its role in oncogenic processes and drug resistance makes it a candidate for future therapeutic intervention[1][3][5].

Other names

TRIB2Tribbles homolog 2Trib2Tribbles protein homolog 2

Inhibition of pseudokinase/scaffold activity (explored for small molecules that block the ATP-binding cleft in mutated TRIB2)[1][3]. Modulation of E3 ubiquitin ligase recruitment and substrate degradation (potential indirect druggable mechanisms)[3].